Feifei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feifei Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Shipeng Li
Department of Hepatopancreaticobiliary Surgery, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, Henan, China
2 shared publications - Chaoxia Zhu
Department of Endocrinology, The First Affiliated Hospital and Clinical Medicine College of Henan University of Science and Technology, Luoyang, Henan, China
1 shared publication - Chun Li
Department of Endocrinology, The First Affiliated Hospital and Clinical Medicine College of Henan University of Science and Technology, Luoyang, Henan, China
1 shared publication - Haibo Lu
Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine , Luoyang 471003
1 shared publication - Haixu Xu
Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education, Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China 2
1 shared publication - Hongwei Jiang
Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 9613095
Downregulation of HULC Induces Ferroptosis in Hepatocellular Carcinoma via Targeting of the miR‐3200‐5p/ATF4 Axis
Hepatocellular carcinoma is a malignant tumor that poses a serious threat to human health. Ferroptosis, which represents an identified type of regulated iron‐dependent cell death, may play an important role in hepatocellular carcinoma. However, it is unclear as to whether ferroptosis is involved with the mechanisms of lncRNA HULC in liver cancer cells. Here, we show that knockdown of HULC increases ferroptosis and oxidative stress in liver cancer cells. We also found changes in some related miRNAs in cells treated with HULC siRNA. Differential miRNA expression levels were determined with the use of high‐throughput sequencing and prediction target genes identified using bioinformatics analysis. HULC was found to function as a ceRNA of miR‐3200‐5p, and miR‐3200‐5p regulates ferroptosis by targeting ATF4, resulting in the inhibition of proliferation and metastasis within HCC cells. In summary, these findings illuminate some of the molecular mechanisms through which downregulation of HULC induces liver cancer cell ferroptosis by targeting the miR‐3200‐5p/ATF4 axis to modulate the development of hepatocellular carcinoma.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 9613095
Open AccessDownregulation of HULC Induces Ferroptosis in Hepatocellular Carcinoma via Targeting of the miR‐3200‐5p/ATF4 Axis
Hepatocellular carcinoma is a malignant tumor that poses a serious threat to human health. Ferroptosis, which represents an identified type of regulated iron‐dependent cell death, may play an important role in hepatocellular carcinoma. However, it is unclear as to whether ferroptosis is involved with the mechanisms of lncRNA HULC in liver cancer cells. Here, we show that knockdown of HULC increases ferroptosis and oxidative stress in liver cancer cells. We also found changes in some related miRNAs in cells treated with HULC siRNA. Differential miRNA expression levels were determined with the use of high‐throughput sequencing and prediction target genes identified using bioinformatics analysis. HULC was found to function as a ceRNA of miR‐3200‐5p, and miR‐3200‐5p regulates ferroptosis by targeting ATF4, resulting in the inhibition of proliferation and metastasis within HCC cells. In summary, these findings illuminate some of the molecular mechanisms through which downregulation of HULC induces liver cancer cell ferroptosis by targeting the miR‐3200‐5p/ATF4 axis to modulate the development of hepatocellular carcinoma.
- 27 September 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (3) , 4044-4056
MiR‐130b increases fibrosis of HMC cells by regulating the TGF‐β1 pathway in diabetic nephropathy
Basement membrane thickening, glomerular hypertrophy, and deposition of multiple extracellular matrix characterize the pathological basis of diabetic nephropathy (DN), a condition which ultimately leads to glomerular and renal interstitial fibrosis. Here, we identified a novel microRNA, miR‐130b, and investigated its role and therapeutic efficacy in alleviating DN. Introduction of miR‐130b dramatically increased cell growth and fibrosis in DN cells. We found that transforming growth factor (TGF)‐β1 was a functional target of miR‐130b in human glomerular mesangial cells (HMCs) and overexpression of miR‐130b increased expressions of the downstream signaling molecules of TGF‐β1, t‐Smad2/3, p‐Smad2/3, and SMAD4. An ectopic application of miR‐130b increased messenger RNA and protein expressions of collagen type I (colI), colIV, and fibronectin, whose expression levels were correlated with the expression of miR‐130b. Taken together, the findings of this study reveal that miR‐130b in HMC cells plays an important role in fibrosis regulation and may thus be involved with the pathogenesis of DN. Therefore, miR‐130b may serve as a novel therapeutic target for the prevention and the treatment of DN.
- 27 September 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (3) , 4044-4056
MiR‐130b increases fibrosis of HMC cells by regulating the TGF‐β1 pathway in diabetic nephropathy
Basement membrane thickening, glomerular hypertrophy, and deposition of multiple extracellular matrix characterize the pathological basis of diabetic nephropathy (DN), a condition which ultimately leads to glomerular and renal interstitial fibrosis. Here, we identified a novel microRNA, miR‐130b, and investigated its role and therapeutic efficacy in alleviating DN. Introduction of miR‐130b dramatically increased cell growth and fibrosis in DN cells. We found that transforming growth factor (TGF)‐β1 was a functional target of miR‐130b in human glomerular mesangial cells (HMCs) and overexpression of miR‐130b increased expressions of the downstream signaling molecules of TGF‐β1, t‐Smad2/3, p‐Smad2/3, and SMAD4. An ectopic application of miR‐130b increased messenger RNA and protein expressions of collagen type I (colI), colIV, and fibronectin, whose expression levels were correlated with the expression of miR‐130b. Taken together, the findings of this study reveal that miR‐130b in HMC cells plays an important role in fibrosis regulation and may thus be involved with the pathogenesis of DN. Therefore, miR‐130b may serve as a novel therapeutic target for the prevention and the treatment of DN.